Uperio (Sacubitril and Valsartan) | 100mg 28 Film Coated Tablets
₦50,515.00
Why customers choose us
- Satisfaction Guaranteed
- Fast delivery
- Secure Payments
- 24/7 Customer assistance
Uperio (Sacubitril and Valsartan) | 100mg 28 Film Coated Tablets is a dual-action heart failure medication combining a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan) in each 100 mg tablet (49 mg sacubitril + 51 mg valsartan), specifically designed for adults with symptomatic heart failure and reduced ejection fraction (NYHA II–IV).
Product Specifications of Uperio (Sacubitril and Valsartan) | 100mg 28 Film Coated Tablets:
| Feature | Details |
|---|---|
| Active Ingredients | Sacubitril 49 mg + Valsartan 51 mg per tablet (total 100 mg). |
| Dosage Form | Film-coated tablet (pale yellow, oval, debossed). |
| Pack Size | 28 tablets |
| Administration | Oral; swallow with water, with or without food. |
| Storage | Room temperature, protect from moisture and light. |
| Manufacturer | Novartis (Italy, approved by NAFDAC July 2023). |
Clinical Benefits:
- Significantly reduces risk of cardiovascular death and first/recurrent hospitalisations due to heart failure.
- Superior to enalapril in improving outcomes in PARADIGM-HF trial.
- Promotes natriuresis and lowers NT-proBNP—key markers for heart failure management.
Usage & Dosage:
-
Initiation: 100 mg twice daily for patients transitioning from ACE inhibitors/ARBs, or not currently on ACE/ARB.
-
Titration: Increase every 2–4 weeks to a target dose of 200 mg twice daily, as tolerated.
-
Special Populations:
-
Renal impairment (eGFR 30–60) or mild hepatic dysfunction: start at 50 mg twice daily.
-
Contraindicated: Severe renal/hepatic impairment, pregnancy, ACE inhibitor overlap (36-hour washout).
-
Contraindications & Warnings:
- Do not use with concurrent ACE inhibitors (due to angioedema risk); maintain a 36‑hour washout period.
- Avoid in pregnancy, hereditary/idiopathic angioedema, severe hepatic impairment, concomitant aliskiren in diabetics/CKD.
- Monitor for hypotension, hyperkalemia, renal function decline, and rare angioedema—especially in Black patients.
Common Side Effects:
- Low blood pressure, hyperkalemia, cough, dizziness, and renal impairment (>1%).
- Rare but serious: angioedema, nephrotoxicity
Prescription Medication, ARNi, Heart Failure, HFrEF, Sacubitril/Valsartan, Novartis, Cardiovascular Therapy
General Inquiries
There are no inquiries yet.
